(Q37111805)

18 August 2017

1 reference

title

Current and emerging chemotherapy treatment strategies for Wilms tumor in North America (English)

1 reference

18 August 2017

1 reference

1 reference

Eric J Gratias

1

1 reference

18 August 2017

Jeffrey S Dome

series ordinal

2

1 reference

18 August 2017

language of work or name

1 reference

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

10

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

115-124

1 reference

The expression of HSP70 and HSP90alpha in children with Wilms tumor.

18 August 2017

cites work

1 reference

12 December 2020

Autologous stem cell transplantation for high-risk pediatric solid tumors

1 reference

12 December 2020

Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors

1 reference

12 December 2020

Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

1 reference

12 December 2020

Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital

1 reference

12 December 2020

Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group

1 reference

12 December 2020

Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report

1 reference

12 December 2020

Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group

1 reference

12 December 2020

Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology

1 reference

12 December 2020

Wilms' tumor: Prognostic factors for patients without metastases at diagnosis.Results of the national Wilms' tumor study

1 reference

12 December 2020

Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology

1 reference

12 December 2020

Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study

1 reference

12 December 2020

Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group

1 reference

12 December 2020

Improved survival in patients with recurrent Wilms tumor: the experience of the Seoul National University Children's Hospital

1 reference

12 December 2020

Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors

1 reference

12 December 2020

Classification of malignant pediatric renal tumors by gene expression

1 reference

12 December 2020

Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry.

1 reference

12 December 2020

Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group

1 reference

12 December 2020

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

1 reference

12 December 2020

Prognostic factors in nonmetastatic, favorable histology Wilms' tumor. Results of the Third National Wilms' Tumor Study

1 reference

12 December 2020

Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group

1 reference

12 December 2020

High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma

1 reference

12 December 2020

Accuracy of current imaging modalities in the diagnosis of synchronous bilateral Wilms' tumor. A report from the National Wilms Tumor Study Group

1 reference

12 December 2020

Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group

1 reference

12 December 2020

Double high-dose chemotherapy with autologous peripheral stem cell rescue in relapsed Wilms' tumor

1 reference

12 December 2020

Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group

1 reference

12 December 2020

Histopathology and prognosis of Wilms tumorResults from the first national wilms' tumor study

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study.

1 reference

12 December 2020

Outcomes in low-risk babies treated with half-dose chemotherapy according to the Third National Wilms' Tumor Study

1 reference

12 December 2020

The treatment of Wilms' Tumor: Results of the second national Wilms' Tumor study

1 reference

12 December 2020

Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group

1 reference

12 December 2020

The relationship between microsubstaging variables, age at diagnosis, and tumor weight of children with stage I/favorable histology Wilms' tumor. A report from the National Wilms' Tumor study

1 reference

12 December 2020

High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.

1 reference

12 December 2020

High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study

1 reference

12 December 2020

The treatment of Wilms' tumor. Results of the national Wilms' tumor study

1 reference

12 December 2020

Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome

1 reference

12 December 2020

Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.

1 reference

12 December 2020

Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group

1 reference

12 December 2020

Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group

1 reference

12 December 2020

Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study

1 reference

12 December 2020

Classification and prognosis in Wilms's tumor

1 reference

12 December 2020

Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital

1 reference

12 December 2020

10.2165/00148581-200810020-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

18 August 2017

1050952655

0 references

1 reference